Home › Funds › Prosight Management, LP › ADCT

Prosight Management, LP position in ADCT

ADC THERAPEUTICS SA · Health Care

Prosight Management, LP reported holding 399,900 shares of ADCT (ADC THERAPEUTICS SA) in its Q3 2026 13F filing — a position valued at US$488K, representing 0.09% of its reported portfolio and ranking #32 among its reported holdings. Prosight Management, LP has disclosed ADCT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)399.90K sh
Reported value held$487.88K
Portfolio Weight0.09%
First reportedQ3 2023
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Prosight Management, LP's ADCT position evolved

Prosight Management, LP first disclosed a stake in ADCT in Q3 2023 at 5,402,041 shares (US$4.8M). The position peaked in Q1 2024 at 7,050,300 shares, worth US$31.7M. Across 13 filings, Prosight Management, LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 399,900 shares valued at US$488K — a reduction of -7,424,849 shares quarter over quarter.. Notable position changes include a 36% increase in Q2 2024 (shares were roughly flat over the following quarter), a 29% trim in Q3 2025 (shares fell 12% over the following quarter), a 95% trim in Q3 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.40M $4.85M New
Q4 2023 6.47M $10.74M Add
Q1 2024 7.05M $31.66M Add
Q2 2024 9.57M $30.24M Add
Q3 2024 9.64M $30.35M Add
Q4 2024 9.52M $18.93M Reduce
Q1 2025 9.54M $13.46M Hold
Q2 2025 10.47M $28.05M Add
Q3 2025 7.47M $29.89M Reduce
Q4 2025 8.48M $29.93M Add
Q1 2026 8.30M $31.12M Reduce
Q2 2026 7.82M $8.37M Reduce
Q3 2026 399.90K $487.88K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ADCT and 13F data

ADCT (ADC THERAPEUTICS SA) is a Health Care company. 28 other funds we track also report a position in ADCT — the largest reported positions include Redmile Group, LLC (US$12.3M), TCG Crossover Management, LLC (US$12.2M), AIGH Capital Management LLC (US$5.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ADCT

All ADCT fund holders →

FAQ

How long has Prosight Management, LP held ADCT?

Prosight Management, LP has disclosed ADCT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Prosight Management, LP's current position in ADCT?

As of Q3 2026, Prosight Management, LP holds 399.90K shares of ADCT (ADC THERAPEUTICS SA), valued at $487.88K, representing 0.09% of its reported portfolio and ranking #32.

Has Prosight Management, LP been buying or selling ADCT?

In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in ADCT. The position peaked in Q1 2024 at 7.05M shares.

Which other funds hold ADCT?

Other major institutional holders of ADCT include Redmile Group, LLC, TCG Crossover Management, LLC, AIGH Capital Management LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.